Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACE: Ponatinib in Refractory CML and Ph+ ALL
NCT01207440Phase 2Completed
- Sponsor
- ARIAD Pharmaceuticals, Inc.
- Start
- Sep 2010
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 2 trial of ponatinib in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), sponsored by ARIAD Pharmaceuticals, Inc.. Started Sep 2010; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01207440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01207440.